June 16, 2021
A single-dose of the targeted radioligand therapy administered with pembrolizumab led to durable objective responses in patients with mCRPC.
June 09, 2021
Neal D. Shore, MD, discusses results from the phase 2 ODENZA trial which explored patient preference between darolutamide and enzalutamide in men with metastatic castration-resistant prostate cancer.
In this video, lead author Edmund M. Qiao discusses study results presented during the 2021 ASCO Annual Meeting which showed an association between increased prostate-specific antigen screening and improved outcomes in younger African American patients.
“Patients of African ancestry were actually less likely to receive comprehensive genomic profiling earlier in their treatment course than patients of European ancestry, and…patients of African ancestry [were] less likely to be treated in clinical trials,” says Jessica Lee, MS.
The regimen was associated with an approximately 2.5-year absolute benefit in median radiographic progression-free survival versus standard care.
June 08, 2021
The phase 3 SWOG S1216 trial compared ADT plus either the novel agent TAK-700 or bicalutamide in patients with newly diagnosed metastatic hormone-sensitive prostate cancer.
Patients with African ancestry were also less likely to be treated on clinical trials versus patients with European ancestry, the investigators reported.
Adding bone-protecting agents to the treatment of men with asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer helped to reduce their risk for fracture.
Neeraj Agarwal, MD, discusses results from the phase 3 SWOG S1216 trial, which compared ADT plus the novel agent TAK-700 or bicalutamide in patients with newly diagnosed metastatic hormone-sensitive prostate cancer.
June 07, 2021
Darolutamide is FDA-approved for the treatment of patients with nonmetastatic castration-resistant prostate cancer.
